阿莫西林克拉维酸钾注射液联合头孢他啶治疗新生儿肺炎的疗效及安全性分析

Efficacy and Safety of Amoxicillin and Clavulanate potassium Injection Combined with Ceftazidime in the Treatment of Neonatal pneumonia

目的研究阿莫西林克拉维酸钾联合头孢他啶静脉注射治疗新生儿肺炎的疗效及安全性分析。方法选取80例新生儿肺炎患儿,采用随机数表法将其分为观察组与对照组,对照组采取阿莫西林克拉维酸钾治疗,观察组采用阿莫西林克拉维酸钾联合头孢他啶静脉注射治疗,比较两组患儿治疗效果、家属满意度以及其安全性。结果观察组临床总有效率为95.00%,对照组临床疗效总有效率为85.00%,两组患儿临床疗效差异无统计学意义(P>0.05);观察组肠道菌群数量要显著少于对照组,差异有统计学意义(P<0.05);两组患儿治疗期间副作用发生情况无统计学意义(P>0.05)。结论运用阿莫西林克拉维酸钾联合头孢他啶治疗或单用阿莫西林克拉维酸钾治疗都有一定的临床疗效,但联合用药对患儿肠道菌群影响较大,会导致菌群失调,引起腹泻等不良反应,今后在治疗时不单要寻求好的临床疗效也要想办法降低对患儿肠道菌群的影响。

Objective To study the efficacy and safety of amoxicillin and clavulanate potassium injection combined with ceftazidime in the treatment of neonatal pneumonia.Methods 80 cases of neonatal pneumonia admitted in our hospital were selected and divided into observation group and control group by random number table.The control group was treated with amoxicillin and clavulanate potassium.The observation group was treated with amoxicillin and clavulanate potassium combined with ceftazidime.The treatment effects,family satisfaction,and safety of the two groups were compared.Results The total effective rate of clinical efficacy in the observation group was 95.00%,and the total effective rate of clinical efficacy in the control group was 85.00%.There was no significant difference in clinical efficacy between the two groups of children(P>0.05).The number of intestinal flora in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05);the incidence of side effects during treatment between the two groups of children was not statistically significant(P>0.05).Conclusion The use of amoxicillin and clavulanate potassium combined with ceftazidime or amoxicillin and clavulanate potassium alone has certain clinical effects.However,the combined use of the drug has a greater impact on the intestinal flora of the child,which will cause imbalance in the flora and cause adverse reactions such as diarrhea.In the future,not only should we seek good clinical efficacy,but also find ways to reduce the impact on the intestinal flora of children.